ATS 2025 at a glance
Prepare for ATS 2025 with LucidQuest’s concise preview, spotlighting key sessions and emerging trends shaping respiratory and critical care medicine.
📅 Build your schedule around the topics that interest you. 📥 Download the ATS 2025_Preview_by_LucidQuest
Dive deeper
Meta Description: Ahead of ATS 2025 in San Francisco, see what to expect across asthma, COPD, fibrosis, pulmonary hypertension, infections, lung cancer, equity initiatives, and AI/ML—curated by LucidQuest.
Suggested Slug: ats-2025-preview-respiratory-critical-care-ai
Keywords: ATS 2025, ATS25, respiratory, pulmonology, asthma, COPD, fibrosis, pulmonary hypertension, infections, lung cancer, equity, AI in healthcare, machine learning, LucidQuest
Key Topics From ATS 2025 Scientific Presentations
Asthma
- Benralizumab boosts +307 mL FEV₁ and relieves nasal symptoms.
- Triple FF/UMEC/VI slashes flares 52%, ED trips 39%, and costs $1.1K.
- Tezepelumab cuts exacerbations 50–79% across triggers. 💨
COPD
- Women lose lung function faster (NOVELTY).
- Acumapimod halves AECOPD readmissions.
- Early BGF trims events 31%.
- ML-based ECM & cell-ratio markers flag early emphysema. 🫧
Fibrosis
- New agents (bersiporocin, inhaled nintedanib, TG2 & GPR87 blockers) plus lipidomics & PARN genetics advance IPF/PPF, yet only 19% meet 2022 guideline criteria. 🌫️
Pulmonary Hypertension
- Sotatercept drops PAH mortality 83% (STELLAR).
- Bosentan & riociguat top PVR/6MWD in inoperable CTEPH.
- BMP9 & hepatic inflammation emerge as fresh targets. 💓
Infections
- Omadacycline clears MABc NTM-PD 56% vs 29%.
- Extended TB therapy adds no relapse edge.
- ETI sustains CF gains (ppFEV₁ +7%, flares –57%). 🦠
Lung Cancer
- Screening uptake lags in Black/Latino groups.
- Chest-trained radiologists cut LDCT errors.
- Survivors face high early CV mortality—cardio-onc vigilance vital. 🎗️
Equity
- Navajo Nation asthma coaching and Belgium’s targeted COVID-vax show local, culturally tuned programs narrow respiratory-care gaps. 🤝
Artificial Intelligence and Machine Learning at ATS 2025
Diagnostic AI
- EfficientNet-B7 & ScreenDx hit AUC ≥ 0.80 for ILD & effusion detection; EB-OCT model classifies UIP with 100% sensitivity/specificity. 🔍
Imaging Quantification
- qCT vascular & airway metrics (BV5/TVV, pruning) pinpoint PH & COPD phenotypes (AUC 0.94) and track fibrosis vs FVC. 🖥️
Therapy Monitoring
- SIVA cough and Rest Assure OSA wearables boost adherence; MAGNIFY digital pack trims COPD treatment failure 23%. ⏱️
Critical Care ML
- TrAcE extubation AUROC 0.86; eCARTv5 sepsis alerts 67% vs 24% sensitivity, guiding earlier ICU action. 🚑
NLP & EHR
- Hybrid NLP detects PE at 94.8% accuracy; LLMs structure OSA symptoms from notes, easing documentation. 📑
Drug Discovery AI
- Docking screens uncover USP21 inhibitors for immune-evasive NSCLC; machine learning refines structure-guided repurposing. ⚗️
📅 Build your schedule around the topics that interest you.
📥 Download the ATS 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.